Articles tagged with: Liz Highleyman

Many Americans still get their HIV diagnosis years after infection

published: December, 07, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Gay Men, Treatment Guidelines -including when to start, Research, Health, Revolving Door, International , Treatment, Guest Authors, Media

Heterosexual men had undiagnosed HIV longer than women who inject drugs or gay and bisexual men (a median of about five years, two years and three years, respectively).From AIDSmap, Liz Highleyman reports.

Many Americans still get their HIV diagnosis years after infection

Many people with HIV in the United States are still being diagnosed with HIV late, and therefore not getting the full therapeutic and prevention benefits of starting antiretroviral therapy (ART) early, according to the latest Vital Signs report from the US Centers for Disease Control and Prevention (CDC), released in advance of World AIDS Day. People at risk for HIV in the US are getting tested more often than they did in the past and are living with HIV for a shorter period of time bef

Many physicians are wary of providing HIV PrEP for young people

published: May, 31, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Youth, Treatment Guidelines -including when to start, Women, Health, Revolving Door, International , Treatment, Guest Authors, Media

From AIDSmap, Liz Highleyman reports: "While 42% of the physicians overall said they were highly or somewhat likely to recommend PrEP, only 34% said they were likely to actually prescribe it."

Many physicians are wary of providing HIV PrEP for young people

Tanya Mullins at the Pediatric Academic Societies Meeting. Photo by Liz Highleyman, hivandhepatitis.com Only about a third of family practice and paediatric providers said they would be likely to prescribe HIV pre-exposure prophylaxis (PrEP) to adolescent patients, underlining the need to educate providers outside the HIV and sexually transmitted disease fields, according to a report at the 2017 Pediatric Academic Societies Meeting last week in San Francisco. Tanya Mullins of Cincinnati Chil

Studies look at brain and cognitive changes in people with HIV as they age

published: March, 22, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, Aging, Conferences, Gay Men, Treatment Guidelines -including when to start, Mental Health, Women, Research, Health, Revolving Door, International , Guest Authors, Media

From AIDSmap, Liz Highleyman reports on several studies looking into the efffects of HIV on brain function.

Studies look at brain and cognitive changes in people with HIV as they age

People with HIV often show persistent signs of cognitive impairment and abnormalities in brain structure despite suppressive antiretroviral therapy (ART), but they do not appear to experience accelerated decline compared to HIV-negative people as they age, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. HIV-associated neurocognitive disorder remains a poorly-understood co-morbidity in HIV-positive people. Wh

Atripla three times weekly maintains HIV viral suppression for 24 weeks

published: July, 14, 2016 Written by // Guest Authors - Revolving Door Categories // Social Media, Research, Health, Revolving Door, International , Treatment, Guest Authors, Media

Aidsmap reports on a study to test whether simplifying treatment with Atripla to three days a week would be less toxic and able to maintain viral suppression.

Atripla three times weekly maintains HIV viral suppression for 24 weeks

This article by Liz Highleyman was produced in collaboration with hivandhepatitis.com and previously appeared on aidsmap.com here. People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for six months, and longer follow-up is planned, according to research presented last month at the ASM Microbe conference in Boston. Fixed-dose comb